Search Results - "Ferron‐Brady, G"
-
1
-
2
P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Published in HemaSphere (05-04-2022)Get full text
Journal Article -
3
Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Published in BLOOD (05-11-2020)“…Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, induced deep and durable responses in patients…”
Get full text
Journal Article Conference Proceeding -
4
P14: DREAMM‐9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
Published in HemaSphere (01-04-2022)Get full text
Journal Article